Unique Ingredient Identifier W4888I119H is listed as a ingredient substance
| RN | 87-69-4 |
| EC | 201-766-0 |
| NCIT | C47744 |
| RXCUI | 37578 |
| PUBCHEM | 444305 |
| MF | C4H6O6 |
| INCHI KEY | FEWJPZIEWOKRBE-JCYAYHJZSA-N |
| SMILES | O[C@H]([C@@H](O)C(O)=O)C(O)=O |
UNII W4888I119H TARTARIC ACID is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| INTRAMUSCULAR | INJECTION | 0.35 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.35 % |
| INTRAMUSCULAR | SOLUTION, INJECTION | 0.23 %W/V |
| INTRAVENOUS | INJECTABLE | 0.5 % |
| INTRAVENOUS | INJECTION | 2 % |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 2 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 2 % |
| INTRAVENOUS | SOLUTION, CONCENTRATE | 0.5 % |
| INTRAVENOUS | SOLUTION, INJECTION | 20 MG/4ML |
| INTRAVENOUS | SOLUTION, INJECTION | 0.23 % |
| IV(INFUSION) | INJECTION | 2 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 2 % |
| ORAL | CAPSULE | 230 mg |
| ORAL | CAPSULE, EXTENDED RELEASE | 260 MG |
| ORAL | CAPSULE, SUSTAINED ACTION | 215.1 MG |
| ORAL | POWDER, FOR SOLUTION | 15 MG/1ML |
| ORAL | SOLUTION | 0.75 %W/W |
| ORAL | SUSPENSION | 10 MG/5ML |
| ORAL | TABLET | 40 MG |
| ORAL | TABLET, COATED | 10 MG |
| ORAL | TABLET, EXTENDED RELEASE | 75 MG |
| ORAL | TABLET, FILM COATED | 30 MG |
| ORAL | TABLET, FOR SUSPENSION | 7 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 45 MG |
| ORAL | TABLET, SUSTAINED ACTION | 29.2 MG |
| RECTAL | SUPPOSITORY | 21.5 MG |
| SUBCUTANEOUS | SOLUTION, INJECTION | 0.23 % |
| SUBLINGUAL | TABLET | 1.5 MG |
| TOPICAL | FILM, CONTROLLED RELEASE | ADJPH |
| TOPICAL | PATCH | 67 MG |
| TOPICAL | PATCH, CONTROLLED RELEASE | NA |